ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
February 18, 2022SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research... -
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA
February 18, 2022SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research...
Pharma Sources Insight January 2025
